Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study David Price, FRCGP,

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial Saifudin.

Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort Rupert C M Jones,

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

David B. Price, FRCGP, Miguel Román-Rodríguez, MD, R

Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Risk of an asthma exacerbation after bariatric surgery in adults

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma Willem M.C. van Aalderen, MD, PhD, Jonathan Grigg,

Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations Peter G. Gibson, MBBS(Hons),

Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence Laurent Laforest, MD, PhD, Manon Belhassen, MSc, Gilles Devouassoux,

The prevalence of severe refractory asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Epidemic asthma and the role of the fungal mold Alternaria alternata

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies Stuart W Stoloff,

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Prenatal adverse life events increase the risk for atopic diseases in children, which is enhanced in the absence of a maternal atopic predisposition

Inhaler reminders improve adherence with controller treatment in primary care patients with asthma Juliet M. Foster, PhD, Tim Usherwood, BSc, MD, BS,

Stanley J. Szefler, MD, Richard J. Martin, MD

Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease Sadeep Shrestha, PhD, Howard W. Wiener,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study Rachel A. Charlton, PhD, Julia M. Snowball,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Etiology of asthma exacerbations

Asthma treatment and asthma prevention: A tale of 2 parallel pathways

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,

Risk of congenital malformations for asthmatic pregnant women using a long-acting β2- agonist and inhaled corticosteroid combination versus higher-dose.

Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes Anick Bérard, MSc, PhD, Odile Sheehy, MSc, Marie-Laure Kurzinger,

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Gene Colice, MD, Richard J

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort Rupert C M Jones,

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy Padmaja Subbarao, MD, MSc, Sandra C. Dorman,

The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study Tetyana.

Phillip Lieberman, MD, Richard A

The mediating effect of microbial colonization on the effect of cesarean section delivery Adrian J. Lowe, PhD, Elizabeth Williamson, PhD, Lennart Bråbäck,

Machine learning, natural language programming, and electronic health records: The next step in the artificial intelligence journey? Neil Mehta, MBBS,

Day-care attendance, position in sibship, and early childhood wheezing: A population- based birth cohort study Nicolaos C. Nicolaou, MD, MPhil, Angela.

Nitric oxide as a clinical guide for asthma management

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Environmental factors and eosinophilic esophagitis

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts Helen Chapel, MA,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study David Price, FRCGP, Richard J. Martin, MD, Neil Barnes, MBBS, FRCP, Paul Dorinsky, MD, Elliot Israel, MD, Nicolas Roche, MD, PhD, Alison Chisholm, MSc, Elizabeth V. Hillyer, DVM, Linda Kemp, BSc, Amanda J. Lee, PhD, Julie von Ziegenweidt, Gene Colice, MD Journal of Allergy and Clinical Immunology Volume 126, Issue 3, Pages 511-518.e10 (September 2010) DOI: 10.1016/j.jaci.2010.06.040 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Distribution of prescribed doses at the index date for patients initiating an ICS (A) and patients receiving their first increase in ICS dose (B) administered by means of an MDI. Prescribed doses were significantly different between treatment cohorts in both the initiation and step-up populations (P ≤ .001). Journal of Allergy and Clinical Immunology 2010 126, 511-518.e10DOI: (10.1016/j.jaci.2010.06.040) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Odds ratios and rate ratios (95% CIs) for outcome measures for HFA-beclomethasone cohorts of initiation and step-up populations, with the fluticasone cohort set as the reference group (odds ratio/rate ratio = 1.0). SABA, Short-acting β-agonist. ∗Adjusted for year of index date, acetaminophen, asthma consultations, rhinitis diagnosis, recorded asthma diagnosis, and cardiac disease diagnosis. †Adjusted for year of index date, acetaminophen, asthma consultations, and rhinitis diagnosis. Journal of Allergy and Clinical Immunology 2010 126, 511-518.e10DOI: (10.1016/j.jaci.2010.06.040) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Selection of eligible patients in the database: unmatched cohorts Selection of eligible patients in the database: unmatched cohorts. BAI, Breath-actuated inhaler; BDP, beclomethasone dipropionate; CFC, chlorofluorocarbon; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FP, fluticasone propionate; pMDI, pressurized MDI. Journal of Allergy and Clinical Immunology 2010 126, 511-518.e10DOI: (10.1016/j.jaci.2010.06.040) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Selection of eligible patients in the database: matching of the cohorts initiating ICS therapy as HFA-beclomethasone or fluticasone administered by means of an MDI (initiation population). FP, Fluticasone propionate; QVAR, HFA-beclomethasone. Journal of Allergy and Clinical Immunology 2010 126, 511-518.e10DOI: (10.1016/j.jaci.2010.06.040) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Selection of eligible patients in the database: matching of the cohorts receiving their first increase in dose of ICS as HFA-beclomethasone or fluticasone administered by means of an MDI (step-up population). FP, Fluticasone propionate; QVAR, HFA-beclomethasone. Journal of Allergy and Clinical Immunology 2010 126, 511-518.e10DOI: (10.1016/j.jaci.2010.06.040) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions